PATENT CLAIM ANALYSIS

Application Number: 16074744
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting KLK3 eRNA expression, which may be useful for treating, preventing, or ameliorating cancer, such as prostate cancer.

Claim (Index 1):
A compound comprising of a modified oligonucleotide 16 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 3 (GAACCTTGGTTAGGCA), wherein the modified oligonucleotide comprises:\n a gap segment consisting of 10 linked deoxynucleosides; a 5\u2032 wing segment consisting of 3 linked nucleosides; and a 3\u2032 wing segment consisting of 3 linked nucleosides; wherein the gap segment is positioned between the 5\u2032 wing segment and the 3\u2032 wing segment; wherein each nucleoside of each wing segment comprises a contrained ethyl (cEt) nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 96.0
- Lexical Diversity: 1.2963
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14050574', '14854281', '14403103', '13436558', '15356947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7092032741365415
- 35 USC 102 Novelty (BERT): 0.4964098790730371
- Combined Prediction Score: 0.6879239346301911
- Mean Citation Score: 234.977594
- Max Citation Score: 266.149
- Similarity Product: 242.10195346093167

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test